Vioxx Recall Claims Attorneys

Serving Philadelphia, Pennsylvania, New Jersey, Delaware, New York & Nationwide

888-VIOXX-CLAIM

FDA News Release
September 30, 2004

FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product

The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal from the market of Vioxx (chemical name rofecoxib), a non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck & Co. FDA today also issued a Public Health Advisory to inform patients of this action and to advise them to consult with a physician about alternative medications.

Merck is withdrawing Vioxx from the market after the data safety monitoring board overseeing a long-term study of the drug recommended that the study be halted because of an increased risk of serious cardiovascular events, including heart attacks and strokes, among study patients taking Vioxx compared to patients receiving placebo. The study was being done in patients at risk of developing recurrent colon polyps.

"Merck did the right thing by promptly reporting these findings to FDA and voluntarily withdrawing the product from the market," said Acting FDA Commissioner Dr. Lester M. Crawford. "Although the risk that an individual patient would have a heart attack or stroke related to Vioxx is very small, the study that was halted suggests that, overall, patients taking the drug chronically face twice the risk of a heart attack compared to patients receiving a placebo."

Dr. Crawford added that FDA will closely monitor other drugs in this class for similar side effects. "All of the NSAID drugs have risks when taken chronically, especially of gastrointestinal bleeding, but also liver and kidney toxicity. They should only be used continuously under the supervision of a physician."

FDA approved Vioxx in 1999 for the reduction of pain and inflammation caused by osteoarthritis, as well as for acute pain in adults and for the treatment of menstrual pain. It was the second of a new kind of NSAID (Cox-2 selective) approved by FDA. Subsequently, FDA approved Vioxx to treat the signs and symptoms of rheumatoid arthritis in adults and children.

At the time that Vioxx and other Cox-2 selective NSAIDs were approved, it was hoped that they would have a lower risk of gastrointestinal ulcers and bleeding than other NSAIDs (such as ibuprofen and naproxen). Vioxx is the only NSAID demonstrated to have a lower rate of these side effects.

Merck contacted FDA on September 27, 2004, to request a meeting and to advise the agency that the long-term study of Vioxx in patients at increased risk of colon polyps had been halted. Merck and FDA officials met the next day, September 28, and during that meeting the company informed FDA of its decision to remove Vioxx from the market voluntarily.

In June 2000, Merck submitted to FDA a safety study called VIGOR (Vioxx Gastrointestinal Outcomes Research) that found an increased risk of serious cardiovascular events, including heart attacks and strokes, in patients taking Vioxx compared to patients taking naproxen. After reviewing the results of the VIGOR study and other available data from controlled clinical trials, FDA consulted with its Arthritis Advisory Committee in February 2001 regarding the clinical interpretation of this new safety information. In April 2002, FDA implemented labeling changes to reflect the findings from the VIGOR study. The labeling changes included information about the increase in risk of cardiovascular events, including heart attack and stroke.

Recently other studies in patients taking Vioxx have also suggested an increased risk of cardiovascular events. FDA was in the process of carefully reviewing these results, to determine whether further labeling changes were warranted, when Merck informed the agency of the results of the new trial and its decision to withdraw Vioxx from the market.

For a free evaluation of your Vioxx claim contact our experienced Vioxx attorneys today. We will evaluate your Vioxx lawsuit and help you get the result you deserve.

We have more $10 million+ results over a 20-year period than any other Pennsylvania law firm, as many as the next three firms combined.The Legal Intelligencer

2

We Care About You

We work closely with you to help ensure you receive every bit of legal, medical, insurance and financial assistance to which you are entitled.

3

Best Attorneys

Seventeen of our attorneys have been named Super Lawyers or “Rising Stars” by the independent rating survey. Tom Kline has been rated No. 1 in PA 15 times in a row and Shanin Specter in the Top 10 year after year.

4

Doctor/Lawyer Team

We have an unmatched staff of five doctor-lawyers working full-time for our firm. No other law firm in the United States has as many physicians on staff.

5

Our Staff

We have more than 40 attorneys and a staff of 110 to serve clients. We promptly pair you with an attorney for a consultation and spare no effort or expense in litigating cases.

6

Legal Care

We are leaders in handling serious personal injury & whistleblower cases. When we go to court, we bring an army of skilled attorneys and experts to seek to achieve the best possible verdict or settlement.

7

Safety Efforts

We care about making things right. In a lot of cases, that means getting you more than just money. Our cases have resulted in safety improvements in medical care, consumer products, mass transit, motor vehicles, public utilities, police conduct and more.

8

Free Consultations

We provide free case reviews and we work on a contingent fee basis, meaning we don’t get paid unless you win.

Search Video and Print Articles

Select from one or more categories to find videos of Kline & Specter in the media.

Practice Area

Sub Category

Case

Attorney

Major Victories

$153M

Verdict against Ford in death of a boy run over by truck with defective parking brake. The then-second largest product liability verdict in the nation. (White) (Jury awarded $52 million in retrial of punitive damages.)

$120M

Verdict against Johnson & Johnson in a vaginal mesh case. The verdict included $100 million in punitive damages and is the largest contested liability verdict in Pennsylvania history. (McFarland)

$109M

The jury verdict included $48 million compensatory and $61 million punitive damages for the family of a woman killed by a fallen electric line. (Goretzka)

$100M

Largest-ever medical malpractice verdict in Pennsylvania, for a baby who suffered severe brain damage due to medical malpractice. (Vlasny)

$96M

Recovery following a verdict for a woman catastrophically injured in a Philadelphia building collapse. Largest personal injury recovery in Pennsylvania history. (Plekan)

$80M

Verdict against J&J for a Media, Pa., woman in a vaginal mesh case. Verdict included $50 million in punitive and $30 million in compensatory damages, the largest compensatory award in the ongoing mesh litigation. (Mesigian)

Kline & Specter handles cases in Pennsylvania, New Jersey, Delaware and New York. For cases outside those states, Kline & Specter works with local attorneys in each state as applicable.

Kline & Specter, PC only provides legal advice after having entered into an attorney client relationship, which our website specifically does not create. It is imperative that any action taken be done on advice of counsel. Because every case is different, the description of awards and cases previously handled do not guarantee a similar outcome in current or future cases. The firm practices law in New Jersey as Kline & Specter. Super Lawyers, Best Lawyers in America and other organizations that rate attorneys are not designations that have been approved by the State Supreme Courts or the American Bar Association.This website is not intended for viewing or usage by European Union citizens.